Clostridioides difficile infection: A growing threat in Argentine hospitals
DOI:
https://doi.org/10.56294/shp2024128Keywords:
Clostridioides difficile, nosocomial diarrhea, antibiotics, hospital-acquired infection, ArgentinaAbstract
The study addressed Clostridioides difficile infection (CDI) as one of the main causes of nosocomial diarrhea in hospitalized patients, especially in older adults and people with comorbidities. We analyzed how the prolonged and inadequate use of antibiotics altered the intestinal microbiota, facilitating colonization of the bacillus. Likewise, the main risk factors were described, including prolonged hospitalization, exposure to broad-spectrum antimicrobials and stay in intensive care units. In the Argentine context of the year 2024, there was a lack of standardized epidemiological data, difficulty in accessing sensitive diagnostic methods and unequal implementation of preventive measures among institutions. The Argentine health system, which was affected by structural tensions, economic limitations and institutional fragmentation, showed difficulties in controlling the spread of CDI, resulting in increased morbidity, prolonged hospitalization and higher hospital costs. Despite these limitations, the study highlighted the importance of strengthening epidemiological surveillance, promoting the rational use of antibiotics, training health personnel and improving infection control programs. Finally, it was concluded that a multidisciplinary approach, supported by sustained health policies and coordinated actions between the public and private sectors, was essential to reduce the incidence of this infection in Argentina and to improve clinical outcomes in vulnerable patients.
References
1. Menéndez M, Batista N, et al. Predictores de riesgo para desarrollo de infección por Clostridium difficile. Rev Med Urug. 2016;32(3).
2. Barcán L, Ducatenzeiler L, et al. Recomendaciones intersociedades para diagnóstico, tratamiento y prevención de las infecciones por Clostridioides difficile. Medicina (B Aires). 2020;80(Supl 1).
3. Becerra MG, Ospina S, et al. Factores de riesgo para la infección por Clostridium difficile. Infectio. 2011;15(4).
4. Al-Zahrani IA. Clostridioides (Clostridium) difficile: a silent nosocomial pathogen. Saudi Med J. 2023;44(9):825–35.
5. Rocha CH, Pidal P, et al. Consenso chileno de prevención, diagnóstico y tratamiento de la diarrea asociada a Clostridium difficile. Rev Chil Infectol. 2016;33(1).
6. Jorge L, Azula N, et al. Incidencia, características clínicas y evolución de la infección por Clostridioides difficile. Medicina (B Aires). 2021;81(6).
7. Arteaga A, Santa-Olalla P, et al. Riesgo epidémico de la enfermedad asociada a una nueva cepa de Clostridium difficile. Enferm Infecc Microbiol Clin. 2009;27(5):278–84.
8. Stevens V, Dumyati G, et al. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis. 2011;53(1):42–8.
9. Owens RC, Donskey CJ, et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl 1):S19–31.
10. Hernández DAÁ, González AM, et al. Perspectivas históricas y vigentes sobre la infección por Clostridium difficile. Rev Gastroenterol Mex. 2018;83(1):41–50.
11. Rocha CH, Naour S, et al. Infecciones causadas por Clostridium difficile: una visión actualizada. Rev Chil Infectol. 2012;29(4).
12. Capello MC. Análisis de pacientes con infección por Clostridium difficile en un nosocomio de segundo nivel de atención de la ciudad de Rosario [especialización en clínica médica]. Rosario: UNR; 2019 [acceso 7 jul 2024]. Disponible en: https://www.clinica-unr.com.ar/Posgrado/trabajos-graduados/capello-celeste.pdf
13. Buffie CG, et al. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun. 2012;80(1):62–73.
14. Surawicz CM, et al. Antibiotic associated diarrhea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials? Chemotherapy. 2005;51(Suppl 1):81–9.
15. Kuijper EJ, Coignard B, et al. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12(Suppl 6):2–18.
16. Dos Santos SLF, Barros KBNT, et al. Infecção por Clostridium difficile associada a antibioticoterapia: fisiopatologia, diagnóstico e tratamento. Rev Cienc Med Campinas. 2017;26(1):19–26.
17. Olvera CGM, Zubiria LL. Clostridioides difficile in Latin America: an epidemiological overview. Curr Microbiol. 2023;80:357.
18. Abad C, Safdar N, et al. A review of Clostridioides difficile infection and antibiotic-associated diarrhea. Gastroenterol Clin North Am. 2021 Jun.
19. Ramirez J, Guarner F, et al. Antibiotics as major disruptors of gut microbiota. Front Cell Infect Microbiol. 2020 Nov.
20. Capurso L, Koch M. Side effects of antibiotics: diarrhea and Clostridium difficile infection. Recenti Prog Med. 2021 Jan.
21. Knecht H, Neulinger S, et al. Effects of β-lactam antibiotics and fluoroquinolones on human gut microbiota in relation to Clostridium difficile-associated diarrhea. PLoS One. 2014 Feb.
22. Gerding D. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis. 2004 Mar.
23. Blondeau JM. What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea? J Antimicrob Chemother. 2009 Feb;63:238–42.
24. Dethlefsen L, Huse S, et al. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008 Nov;6(11):e280.
25. Croswell A, Amir E, et al. Prolonged impact of antibiotics on intestinal microbial ecology and susceptibility to enteric Salmonella infection. Infect Immun. 2009 Apr;77(7):2741–53.
26. Deshpande A, Pasupuleti V, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother. 2013 Sep;68(9):1951–61.
27. Rafey A, Jahan S, et al. Antibiotics associated with Clostridium difficile infection. Cureus. 2023 May.
28. Mullish BH, Williams HR, et al. Clostridium difficile infection and antibiotic-associated diarrhoea. Clin Med (Lond). 2018 Jun;18(3):237–41.
29. Stevens V, Dumyati G, et al. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis. 2011 Jul 1;53(1):42–8.
30. Hensgens MPM, Goorhuis A, et al. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012 Mar;67(3):742–8.
31. Brown KA, Khanafer N, et al. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother. 2013 Apr;57(5):2326–32.
32. Brown KA, Langford B, et al. Antibiotic prescribing choices and their comparative Clostridium difficile infection risks: a longitudinal case-cohort study. Clin Infect Dis. 2021 Mar;72(5):836–44.
33. Slimings C, Riley TV, et al. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother. 2014 Apr;69(4):881–91.
34. Tariq R, Cho J, et al. Low risk of primary Clostridium difficile infection with tetracyclines: a systematic review and meta-analysis. Clin Infect Dis. 2018 Feb;66(4):514–22.
35. Webb BJ, Subramanian A, et al. Antibiotic exposure and risk for hospital-associated Clostridioides difficile infection. Antimicrob Agents Chemother. 2020 Mar;64(4):e02169-19.
36. Tabak YP, Srinivasan A, et al. Hospital-level high-risk antibiotic use in relation to hospital-associated Clostridioides difficile infections: retrospective analysis of 2016–2017 data from US hospitals. Infect Control Hosp Epidemiol. 2019 Nov;40(11):1229–35.
37. Wilcox MH, Chalmers JD, et al. Role of cephalosporins in the era of Clostridium difficile infection. J Antimicrob Chemother. 2017 Jan;72(1):1–18.
38. Büchler AC, Rampini SK, et al. Antibiotic susceptibility of Clostridium difficile is similar worldwide over two decades despite widespread use of broad-spectrum antibiotics: an analysis done at the University Hospital of Zurich. BMC Infect Dis. 2014 Nov;14:607.
39. Pepin J, Saheb N, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005 Sep;41:1254–60.
Published
Issue
Section
License
Copyright (c) 2024 Francy Ellen De Lima , Gerardo Erico Laube (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
